Abstracts

971 – Patient and Provider Preferences for Long-Acting Tuberculosis Preventive Therapy

Background Tuberculosis preventive therapy (TPT) is a key intervention for tuberculosis (TB) elimination. The introduction of long acting (LA) TPT has the potential to enhance adherence, minimize treatment interruptions, improve completion rates, and extend protection against tuberculosis. Methods We conducted a cross-sectional in-person survey among patients in two high-burden TB countries to evaluate preferences, and concerns…

969 – The Impact of Rifampin Drug Interactions on TPT Completion and Safety Using High-Dose vs Standard

Background Tuberculosis preventive treatment (TPT) has been recognized by the World Health Organization as a critical intervention to eliminate tuberculosis. Rifampin TPT is critical to this goal, given high completion rates, short treatment lengths, and low side-effects. However, rifampin treatment has limitations by drug-drug interactions (DDI) with multiple medications   Methods A post-hoc data analysis…

970 – Weekly Rifapentine and Isoniazid (3HP) vs Isoniazid Preventive Therapy (6H) Among People With HIV

Background People with HIV (PHIV) have a 30% lifetime risk of developing tuberculosis (TB) disease, which TB preventive therapy (TPT) reduces by 60%. Six-month daily isoniazid (6H) regimens are challenged by non-adherence and suboptimal completion. Shorter regimens such as 3-month weekly rifapentine and isoniazid (3HP) were introduced in Kenya in October 2022. There is a…

972 – Effect of Tuberculosis Preventive Therapy on Mtb-Specific T-Cell Profile in the A5279/BRIEF TB Trial

Background People with HIV (PWH) have impaired Mycobacterium tuberculosis (Mtb)-specific T cell responses, making induction of effective immunity challenging. Whether TB preventive therapy (TPT) modifies Mtb-specific T cell profile in PWH is unknown. We interrogated Mtb antigen-specific T cell responses in PWH with latent TB infection (LTBI) pre- and post-TPT within the ACTG A5279 clinical…

936 – Preserved Adrenal Function in People With Long COVID

Background Low serum cortisol has been associated with long COVID (LC) in some but not all studies. However, these studies examined untimed cortisol levels, which may not adequately assess adrenal function. Here we assessed untimed, timed, and stimulated cortisol levels and tested their association with LC. Methods Untimed total cortisol levels were quantified in 711…

813 – Mitochondrial Haplogroups and Left Ventricular Dysfunction in People Living With and Without HIV

Background Mitochondrial dysfunction is implicated in the development of heart failure, which is more common in people with HIV (PWH) than those without HIV (PWoH). Whether genetic variations in mitochondrial DNA (mtDNA) are related to cardiac dysfunction, specifically left ventricular diastolic dysfunction (LVDD), has not been well studied in PWH. Methods We included men from…

815 – Readmission Risk for Adults With HIV Hospitalized for Heart Failure or Acute Myocardial Infarction

Background People with HIV (PWH) have a higher incidence of cardiovascular disease, including heart failure (HF) and acute myocardial infarction (AMI) than people without HIV (PWoH). In the general population, 30-day readmissions following hospitalizations for HF and AMI are common, and reducing these readmissions is a national quality of care priority. This study compares the 30-day…

794 – Causes of Death Among Adults With HIV-Associated Kaposi Sarcoma in East Africa in the Treat All Era

Background In East Africa, one-year mortality following a diagnosis of HIV-associated Kaposi sarcoma (KS) in the Treat All era was recently estimated, in a community-derived sample, to be 41%.  To date, there is limited information on why these patients die.  Understanding causes of death among adults diagnosed with KS might improve management and, hence, survival or…